Fairmount Funds Management LLC 13D and 13G filings for Inhibikase Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 3:45 pm Purchase | 2024-12-31 | 13G | Inhibikase Therapeutics, Inc. IKT | Fairmount Funds Management LLC | 7,018,575 9.900% | 398,264 (+6.02%) | Filing |
| 2024-10-17 7:00 pm Purchase | 2024-10-09 | 13G | Inhibikase Therapeutics, Inc. IKT | Fairmount Funds Management LLC | 6,620,311 9.900% | 6,620,311 (New Position) | Filing |